NO319993B1 - Fremgangsmate for fremstilling av et granulat omfattende <beta>-laktam-antibiotikum, hurtig-desintgrerende,oral doseringsform amt fremgangsmate for fremstilling av denne- - Google Patents
Fremgangsmate for fremstilling av et granulat omfattende <beta>-laktam-antibiotikum, hurtig-desintgrerende,oral doseringsform amt fremgangsmate for fremstilling av denne- Download PDFInfo
- Publication number
- NO319993B1 NO319993B1 NO19973646A NO973646A NO319993B1 NO 319993 B1 NO319993 B1 NO 319993B1 NO 19973646 A NO19973646 A NO 19973646A NO 973646 A NO973646 A NO 973646A NO 319993 B1 NO319993 B1 NO 319993B1
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- weight
- antibiotic
- granulate
- mixture
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 20
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims abstract description 30
- 239000002132 β-lactam antibiotic Substances 0.000 claims abstract description 28
- 229940124586 β-lactam antibiotics Drugs 0.000 claims abstract description 28
- 239000002552 dosage form Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920002678 cellulose Polymers 0.000 claims abstract description 18
- 239000001913 cellulose Substances 0.000 claims abstract description 17
- 238000005550 wet granulation Methods 0.000 claims abstract description 13
- 239000011230 binding agent Substances 0.000 claims abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 21
- 235000010980 cellulose Nutrition 0.000 claims description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000002360 explosive Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 5
- 229930195708 Penicillin V Natural products 0.000 claims description 5
- 229940056367 penicillin v Drugs 0.000 claims description 5
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229930186147 Cephalosporin Natural products 0.000 claims description 4
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 4
- 229940124587 cephalosporin Drugs 0.000 claims description 4
- 150000001780 cephalosporins Chemical class 0.000 claims description 4
- 229960004273 floxacillin Drugs 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims 1
- 235000016257 Mentha pulegium Nutrition 0.000 claims 1
- 235000004357 Mentha x piperita Nutrition 0.000 claims 1
- 235000001050 hortel pimenta Nutrition 0.000 claims 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 claims 1
- 229960004894 pheneticillin Drugs 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 abstract description 5
- 239000003826 tablet Substances 0.000 description 29
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 17
- 239000007788 liquid Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229920003084 Avicel® PH-102 Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229960004920 amoxicillin trihydrate Drugs 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- -1 ampicillin trihydrates Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DQECFVGMGBQCPA-GLCLSGQWSA-N 2,2-dimethylpropanoyloxymethyl (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydron;chloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DQECFVGMGBQCPA-GLCLSGQWSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 description 1
- QFWPXOXWAUAYAB-XZVIDJSISA-M carindacillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 QFWPXOXWAUAYAB-XZVIDJSISA-M 0.000 description 1
- JKXQBIZCQJLVOS-GSNLGQFWSA-N clometocillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(OC)C1=CC=C(Cl)C(Cl)=C1 JKXQBIZCQJLVOS-GSNLGQFWSA-N 0.000 description 1
- 229960001351 clometocillin Drugs 0.000 description 1
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 description 1
- 229960003026 cloxacillin sodium Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004060 dicloxacillin sodium Drugs 0.000 description 1
- SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- QRSPJBLLJXVPDD-XFAPPKAWSA-M hetacillin potassium Chemical compound [K+].C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 QRSPJBLLJXVPDD-XFAPPKAWSA-M 0.000 description 1
- 229960002041 hetacillin potassium Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 229960001775 nafcillin sodium Drugs 0.000 description 1
- OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003994 oxacillin sodium Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 229960004632 pivampicillin hydrochloride Drugs 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- HOCWPKXKMNXINF-XQERAMJGSA-N propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 description 1
- 229960003672 propicillin Drugs 0.000 description 1
- 102220289725 rs778831047 Human genes 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- LFBBSWBQNQXKPF-LQDWTQKMSA-M sodium;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 LFBBSWBQNQXKPF-LQDWTQKMSA-M 0.000 description 1
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95200313 | 1995-02-08 | ||
| PCT/EP1996/000547 WO1996024337A1 (en) | 1995-02-08 | 1996-02-08 | ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO973646D0 NO973646D0 (no) | 1997-08-07 |
| NO973646L NO973646L (no) | 1997-09-11 |
| NO319993B1 true NO319993B1 (no) | 2005-10-10 |
Family
ID=8220003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19973646A NO319993B1 (no) | 1995-02-08 | 1997-08-07 | Fremgangsmate for fremstilling av et granulat omfattende <beta>-laktam-antibiotikum, hurtig-desintgrerende,oral doseringsform amt fremgangsmate for fremstilling av denne- |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5948422A (bg) |
| EP (1) | EP0801559B1 (bg) |
| CN (1) | CN1125636C (bg) |
| AT (1) | ATE216576T1 (bg) |
| AU (1) | AU4789696A (bg) |
| BG (1) | BG63528B1 (bg) |
| BR (1) | BR9607189A (bg) |
| CZ (1) | CZ293718B6 (bg) |
| DE (1) | DE69620866T2 (bg) |
| DK (1) | DK0801559T3 (bg) |
| EA (2) | EA003736B1 (bg) |
| ES (1) | ES2175073T3 (bg) |
| HU (1) | HU227938B1 (bg) |
| MX (1) | MX9706062A (bg) |
| NO (1) | NO319993B1 (bg) |
| PL (1) | PL186386B1 (bg) |
| PT (1) | PT801559E (bg) |
| WO (1) | WO1996024337A1 (bg) |
| ZA (1) | ZA961018B (bg) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI225402B (en) * | 1996-03-13 | 2004-12-21 | Biochemie Gmbh | Auxiliary-free agglomerates |
| EP0912169A2 (en) | 1996-07-16 | 1999-05-06 | Gist-Brocades B.V. | $g(b)-LACTAM GRANULES FREE OF ORGANIC SOLVENTS |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
| PT1058538E (pt) * | 1998-03-06 | 2002-11-29 | Eurand Int | Comprimidos de desintegracao rapida |
| US7399751B2 (en) * | 1999-11-04 | 2008-07-15 | Sertoli Technologies, Inc. | Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells |
| DE19922537A1 (de) * | 1999-05-10 | 2000-11-16 | Roland Bodmeier | Darreichungsform zur Applikation in Körperöffnungen |
| CA2423329A1 (en) * | 2000-09-22 | 2003-03-20 | Takeda Chemical Industries, Ltd. | Solid preparations |
| GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
| EP1368003A4 (en) * | 2001-02-05 | 2004-05-12 | Scherer Technologies Inc R P | METHODS AND COMPOSITIONS FOR REDUCING THE TASTE OF PHARMACEUTICAL ACTIVE SUBSTANCES |
| WO2003077842A2 (en) * | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | Palatable oral suspension and method |
| DE60334391D1 (de) * | 2002-10-02 | 2010-11-11 | Meiji Seika Kaisha | Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen |
| JP4708795B2 (ja) * | 2002-12-20 | 2011-06-22 | ニコノヴァム エービー | 物理的および化学的に安定なニコチン−含有粒状物質 |
| EP1648380B1 (en) * | 2003-07-03 | 2015-04-08 | Sertoli Technologies, LLC | Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
| US20050089502A1 (en) * | 2003-08-21 | 2005-04-28 | Todd Schansberg | Effervescent delivery system |
| KR101432313B1 (ko) * | 2005-11-17 | 2014-08-20 | 노파르티스 아게 | 약제학적 조성물 |
| CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| AU2007278850B2 (en) * | 2006-07-28 | 2013-06-06 | Sertocell Biotechnology (Us) Corp. | Adult sertoli cells and uses thereof |
| WO2010031552A1 (en) * | 2008-09-17 | 2010-03-25 | Niconovum Ab | Process for preparing snuff composition |
| CA2746768A1 (en) * | 2008-12-17 | 2010-07-08 | Altheus Therapeutics, Inc. | Enema formulations |
| WO2023204773A1 (en) * | 2022-04-20 | 2023-10-26 | Bilim Ilac Sanayii Ve Ticaret A.S. | Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3344030A (en) * | 1964-06-15 | 1967-09-26 | American Home Prod | Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables |
| DE2251249A1 (de) * | 1972-10-19 | 1974-05-02 | Hoechst Ag | Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten |
| DE2251250C3 (de) * | 1972-10-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten |
| ES2061623T3 (es) * | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
| US5049394A (en) * | 1987-09-11 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Pharmaceutical composition containing high drug load and method for preparing same |
| ATE108996T1 (de) * | 1988-02-25 | 1994-08-15 | Brocades Pharma Bv | Verfahren zur herstellung eines pharmazeutischen granulats. |
| US5643591A (en) * | 1991-01-16 | 1997-07-01 | Fmc Corporation | Solid dosage forms |
| JPH09512015A (ja) * | 1994-04-13 | 1997-12-02 | リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド | セルトーリ細胞および同種移植片または異種移植片を用いる疾患処置方法 |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
-
1996
- 1996-02-08 EA EA199900205A patent/EA003736B1/ru not_active IP Right Cessation
- 1996-02-08 PT PT96904039T patent/PT801559E/pt unknown
- 1996-02-08 CZ CZ19972302A patent/CZ293718B6/cs not_active IP Right Cessation
- 1996-02-08 DK DK96904039T patent/DK0801559T3/da active
- 1996-02-08 MX MX9706062A patent/MX9706062A/es unknown
- 1996-02-08 US US08/894,602 patent/US5948422A/en not_active Expired - Lifetime
- 1996-02-08 EP EP96904039A patent/EP0801559B1/en not_active Expired - Lifetime
- 1996-02-08 PL PL96321567A patent/PL186386B1/pl unknown
- 1996-02-08 EA EA199700093A patent/EA000361B1/ru not_active IP Right Cessation
- 1996-02-08 DE DE69620866T patent/DE69620866T2/de not_active Expired - Lifetime
- 1996-02-08 ES ES96904039T patent/ES2175073T3/es not_active Expired - Lifetime
- 1996-02-08 WO PCT/EP1996/000547 patent/WO1996024337A1/en active IP Right Grant
- 1996-02-08 AU AU47896/96A patent/AU4789696A/en not_active Abandoned
- 1996-02-08 HU HU9801677A patent/HU227938B1/hu not_active IP Right Cessation
- 1996-02-08 CN CN96191852A patent/CN1125636C/zh not_active Expired - Fee Related
- 1996-02-08 BR BR9607189A patent/BR9607189A/pt active Search and Examination
- 1996-02-08 ZA ZA9601018A patent/ZA961018B/xx unknown
- 1996-02-08 AT AT96904039T patent/ATE216576T1/de active
-
1997
- 1997-08-07 NO NO19973646A patent/NO319993B1/no not_active IP Right Cessation
- 1997-08-08 BG BG101822A patent/BG63528B1/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0801559B1 (en) | 2002-04-24 |
| CN1173816A (zh) | 1998-02-18 |
| DE69620866T2 (de) | 2003-02-27 |
| WO1996024337A1 (en) | 1996-08-15 |
| HUP9801677A2 (hu) | 1998-11-30 |
| HU227938B1 (en) | 2012-06-28 |
| EA199900205A1 (ru) | 2000-06-26 |
| DE69620866D1 (de) | 2002-05-29 |
| NO973646L (no) | 1997-09-11 |
| BR9607189A (pt) | 1997-11-11 |
| AU4789696A (en) | 1996-08-27 |
| PL186386B1 (pl) | 2004-01-30 |
| PL321567A1 (en) | 1997-12-08 |
| ATE216576T1 (de) | 2002-05-15 |
| EA003736B1 (ru) | 2003-08-28 |
| BG101822A (bg) | 1998-04-30 |
| MX9706062A (es) | 1997-10-31 |
| CZ293718B6 (cs) | 2004-07-14 |
| CZ230297A3 (en) | 1997-11-12 |
| US5948422A (en) | 1999-09-07 |
| BG63528B1 (bg) | 2002-04-30 |
| CN1125636C (zh) | 2003-10-29 |
| DK0801559T3 (da) | 2002-06-17 |
| EP0801559A1 (en) | 1997-10-22 |
| EA199700093A1 (ru) | 1998-02-26 |
| ES2175073T3 (es) | 2002-11-16 |
| ZA961018B (en) | 1997-08-08 |
| PT801559E (pt) | 2002-09-30 |
| EA000361B1 (ru) | 1999-06-24 |
| NO973646D0 (no) | 1997-08-07 |
| HUP9801677A3 (en) | 1999-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO319993B1 (no) | Fremgangsmate for fremstilling av et granulat omfattende <beta>-laktam-antibiotikum, hurtig-desintgrerende,oral doseringsform amt fremgangsmate for fremstilling av denne- | |
| ES2347968T3 (es) | Preparacion solida que se disgrega rapidamente. | |
| US10441585B2 (en) | Formulations containing nalbuphine and uses thereof | |
| NO320767B1 (no) | Granulat for fremstilling av hurtig desintegrerende og hurtig oppløselige blandinger inneholdende en høy mengde aktiv bestanddel | |
| HU201867B (en) | Process for producing in water dispergatable tablets | |
| JP2001512451A (ja) | アモキシシリンおよびクラブラン酸塩を含む医薬処方 | |
| IE53543B1 (en) | New oral dipyridamole preparations | |
| JP2001522874A (ja) | オメプラゾールの配合物 | |
| KR20040002976A (ko) | 옥스카르바제핀 제형 | |
| AU759517B2 (en) | Compositions comprising cefuroxime axetil | |
| US6565877B1 (en) | Taste masked compositions | |
| JPH10504295A (ja) | 医薬処方 | |
| EP1194124B1 (en) | Taste masked compositions | |
| EP2726063A1 (en) | Ibuprofen chewable tablet | |
| EP0948318B1 (en) | Granulates comprising a water soluble compound and cellulose | |
| NO164958B (no) | Fremgangsmaate for fremstilling av dipyridamol-preparater med ph-uavhengig, regulert frigjoering. | |
| WO2011093821A1 (en) | Effervescent formulations comprising cefdinir and clavulanic acid | |
| JP2024003789A (ja) | 時限放出型顆粒およびその用途 | |
| NO323835B1 (no) | Faststoff-preparat med hoy absorpsjonsevne | |
| JP2004315424A (ja) | 苦味を低減した薬物含有速放性顆粒 | |
| MXPA99001493A (es) | Granulados que comprenden un compuesto soluble en agua y celulosa | |
| AU7933001A (en) | Granulates comprising a water soluble compound and cellulose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |